Search Results
Your search for ,had matches 18600 pages
Showing 6551 - 6600Proportion of Never-Smokers Among Patients With Lung Cancer in Seven U.S. States
In a study reported in a research letter in JAMA Oncology, Siegel et al found that never-smokers accounted for 12.5% of patients diagnosed with lung cancer in seven U.S. states during a recent 6-year period, with women accounting for a higher proportion than men. Study Details The study included...
ASH 2020: Chemotherapy Plus Blinatumomab for Philadelphia Chromosome–Negative B-Cell ALL
Results from a phase II study presented by Nicholas J. Short, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 464) showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab...
ASH 2020: Study Finds Asciminib Safer, More Effective Than Bosutinib in Chronic Phase CML
Since the introduction of imatinib almost 18 years ago, similar next-generation tyrosine kinase inhibitors have been approved for chronic myeloid leukemia (CML), including dasatinib, nilotinib, bosutinib, and ponatinib. These drugs attack a similar target, making it more likely that resistance to...
ZUMA-5 Trial Finds Axicabtagene Ciloleucel Shows Activity in Patients With Indolent Non-Hodgkin Lymphoma
In the phase II ZUMA-5 trial, axicabtagene ciloleucel led to responses in 92% of patients with indolent non-Hodgkin lymphoma treated with the cellular immunotherapy. These findings were reported by Caron Jacobson, MD, MMSc, and colleagues at the 2020 American Society of Hematology (ASH) Annual...
ASH 2020: Multiple Myeloma Patient Similarity Network Identifies Prognostic Subgroups With Distinct Genetic and Clinical Features
An analysis by Bhalla et al of multiomics data from newly diagnosed patients with multiple myeloma has identified 3 main patient groups and 12 prognostic subgroups (as well as potential vulnerabilities in each subgroup) based on five data types generated from genomic and transcriptomic patient...
ASH 2020: Role of Venetoclax in High-Risk Myeloid Malignancies
The BCL2 inhibitor venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers, and in early studies, the combination showed improved outcomes, according to two reports presented by Jacqueline S. Garcia, MD, and colleagues at the 2020 American Society of Hematology ...
ASH 2020: Subcutaneous Teclistamab for Relapsed or Refractory Multiple Myeloma Studied in Phase I Trial
A subcutaneous injection of the BCMAxCD3 bispecific antibody teclistamab was found to be safe and elicited responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study presented by Alfred L. Garfall, MD, and...
ASH 2020: Novel Antibody-Drug Conjugate Shows Activity in Rare, Aggressive Form of Leukemia
A phase I/II study found that IMGN632, a novel CD123-targeting antibody-drug conjugate, was tolerable and resulted in a 29% overall response rate in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but aggressive form of leukemia. Treatment with the...
ASH 2020: Clonal Hematopoiesis in Donors Aged 40 and Older May Be Linked to Improved Survival in Stem Cell Transplant Recipients
A study presented by Christopher Gibson, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 80) has revealed for the first time that clonal hematopoiesis may confer a health benefit in allogeneic stem cell or bone marrow transplants....
ASH 2020: Early Research Shows CD58 May Be a Biomarker for Response to Axicabtagene Ciloleucel in Patients With Large B-Cell Lymphoma
Although the immunotherapy axicabtagene ciloleucel has significantly improved treatment outcomes for some patients with large B-cell lymphoma, not all patients benefit. In a new study presented by Robbie G. Majzner, MD, and colleagues at the 2020 American Society of Hematology (ASH) Annual Meeting ...
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplant May Improve Survival in Older Patients With High-Risk MDS
Stem cell transplants are not frequently offered to older patients with high-risk myelodysplastic syndromes (MDS). According to a study from the Blood and Marrow Transplant Clinical Trials Network (BMTCTN 1102), these patients may indeed achieve a survival benefit from stem cell transplant. As...
ASH 2020: Vital Information on Patients With COVID-19 and Hematologic Malignancies Provided by ASH Research Collaborative Data Hub
The ASH Research Collaborative COVID-19 Registry for Hematology provides up-to-date information on outcomes and the course of illness for a group of patients with hematologic malignancies and COVID-19. In general, registry data showed that hematologic malignancies increase the risk of severity of...
ASH 2020: APOLLO Findings Support Use of Subcutaneous Daratumumab Plus Pomalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma
For patients with relapsed or refractory multiple myeloma whose disease progressed after at least one prior regimen, the subcutaneous form of daratumumab, given with pomalidomide and dexamethasone, significantly improved progression-free survival vs pomalidomide and low-dose dexamethasone alone....
ASH 2020: Ruxolitinib for Steroid-Refractory/Steroid-Dependent Chronic Graft-vs-Host Disease
Ruxolitinib was superior to best available therapy in achieving efficacy as determined by overall response and duration of response, with acceptable safety in adolescents and adults with steroid-dependent or steroid-refractory chronic graft-vs-host disease. Findings from the phase III REACH3 trial...
Options for Maintenance Therapy for Metastatic Pancreatic Cancer
Pancreatic cancer remains one of the most difficult-to-treat cancer types. Although there have been some advances in the past few years, the needle has not moved much on survival and prognosis. An important issue for those patients with metastatic pancreatic cancer who respond to front-line...
ASH 2020: Study Finds Prophylactic Tranexamic Acid Has No Effect on Bleeding in Patients With Hematologic Malignancies
The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with hematologic malignancies who also received routine prophylactic platelet transfusions, according to findings presented by Terry B. Gernsheimer, MD, and...
ASH 2020: Does Race Contribute to Poor Outcomes in Younger Black Patients Diagnosed With AML?
It has been well documented that, collectively, Black individuals have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers. Black men also have the highest cancer incidence. Although the causes of these inequities are complex, a study by...
The COVID-19 Pandemic and Cancer Care for Older Patients in the United States: Effect on Diagnosis and Treatment
In a study of data from a Medicare fee-for-service population reported in JCO Clinical Cancer Informatics, Debra Patt, MD, PhD, MBA, and colleagues found that the COVID-19 pandemic has resulted in a “substantial decrease in cancer screenings, visits, therapy, and surgeries among older patients with ...
Analysis of Adjuvant Therapies for Early-Stage Triple-Negative Breast Cancer
In a population-based cohort study reported in JAMA Network Open, Zhai et al found that adjuvant therapies were associated with improved overall survival among patients with stage I (T1 N0 M0) triple-negative breast cancer, with adjuvant chemotherapy being associated with improved breast...
Complexity of Designing Clinical Trials for Sarcoma: Shifting Focus to Constellation of Subtypes
Sarcoma has bedeviled researchers for many years because of its heterogeneity. Sarcoma encompasses more than 100 different subtypes, which makes it difficult to design studies to identify effective therapies. As researchers dig deeper into the constellation of subtypes of sarcoma, some therapies...
Statins Reduced Risk of Colorectal Cancer in Meta-analysis
A systematic meta-analysis has shown that statin users had a significantly reduced risk of colorectal cancer. The study included patients with and without inflammatory bowel disease, which is associated with an increased risk of this type of cancer. The largest chemopreventive effect was observed...
Study Shows Regional Variation in Genomic Testing for Men With Prostate Cancer
A study published by Michael S. Leapman, MD, and colleagues in JAMA Oncology found substantial regional variation in the use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies. “Little was known...
Association of Fall and Fracture Risk With Androgen Receptor Inhibitor Therapy for Prostate Cancer
In a systematic review and meta-analysis reported in JAMA Network Open, Myint et al found that androgen receptor inhibitor therapy for prostate cancer was associated with an increased risk of both falls and fractures. Study Details The meta-analysis included 11 randomized trials reported through...
Study Explores Duration of Shedding of Viable SARS-CoV-2 in Patients With Cancer After Immunosuppressive Therapy
In a single-institution study reported in a letter to the editor in The New England Journal of Medicine, Aydillo et al found that SARS-CoV-2 RNA could be detected in patients with COVID-19 receiving immunosuppressive treatment for cancer for as long as 78 days after the onset of virus symptoms. The ...
FDA Pipeline: Agents in DLBCL, SCLC, AML, and More
Recently, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions for agents to treat diffuse large B-cell lymphoma (DLBCL), small cell lung cancer (SCLC), acute myeloid leukemia (AML), biliary tract cancer, and graft-vs-host disease. Priority Review for Loncastuximab Tesirine...
Subgroup Analysis of Japanese Patients With Ovarian Cancer Treated With Maintenance Olaparib/Bevacizumab
Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented by Fujiwara et al at the ESMO Asia Virtual Congress 2020 showed that the addition of olaparib to bevacizumab maintenance following standard platinum-based therapy plus bevacizumab provided a progression-free...
Social Needs May Be Linked to Low Health-Related Quality of Life Among Black Cancer Survivors
Social needs—such as food and economic insecurity, poor housing and neighborhood conditions, and lack of access to transportation—were common in a group of Black cancer survivors in Detroit. These factors were associated with lower health-related quality of life, according to findings published by...
Definitive SBRT and Outcomes in Adult Patients With Extracranial Oligometastasis
In a retrospective case series reported in JAMA Network Open, Poon et al found that definitive stereotactic body radiotherapy (SBRT) was associated with good long-term overall survival and delayed widespread disease progression—but “modest” progression-free survival—in adults with extracranial...
Managing Checkpoint Inhibitor–Mediated Colitis: Vedolizumab vs Infliximab
For patients who develop severe diarrhea or colitis while receiving checkpoint inhibitors, the immunosuppressive agent vedolizumab is preferred over infliximab, according to an expert on the topic from The University of Texas MD Anderson Cancer Center. A retrospective comparison of outcomes with...
FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
On December 1, the U.S. Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, or for patients with RET fusion–positive thyroid cancer...
FDA Approves Gallium-68 PSMA-11 for PSMA-Targeted PET Imaging in Prostate Cancer
On December 1, the U.S. Food and Drug Administration (FDA) approved gallium-68 PSMA-11—the first drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Gallium-68 PSMA-11 is indicated for patients with suspected ...
Phase II Study of Combination Immunotherapy for Advanced Nasopharyngeal Cancer
Dual CTLA-4/PD-1 blockade with ipilimumab plus nivolumab provided durable responses in patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated efficacy and safety findings from a phase II study presented by Kao et al at ESMO Asia Virtual Congress 2020 (Abstract 266O)....
Does Concurrent Treatment With Dexamethasone Diminish the Efficacy of Immune Checkpoint Inhibitors in Patients With Glioblastoma?
Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results of a study published by Iorgulescu et al in Clinical Cancer Research....
Avelumab Maintenance vs Continued Chemotherapy After First-Line Induction for Advanced Gastric Cancer
As reported in the Journal of Clinical Oncology by Markus Moehler, MD, and colleagues, the phase III JAVELIN Gastric 100 trial showed no improvement in overall survival with avelumab maintenance vs continued chemotherapy after first-line induction in HER2-negative, unresectable, locally advanced or ...
Discordance Among Risk Models for Smoldering Multiple Myeloma
In a study reported as a research letter in JAMA Oncology, Hill et al found a low degree of concordance in risk categorization among commonly used smoldering multiple myeloma risk models. Study Details The study involved application of the Mayo Clinic Risk Stratification Model 2008, the Programa...
Trends in Positive BRCA Test Results Among Women Aged 65 and Older in the United States
In a study reported in JAMA Network Open, Guo et al found that the proportion of positive BRCA genetic test results markedly declined between 2008 and 2018 among women aged ≥ 65 years in the United States, with the trend likely reflecting what the investigators call a loosening of testing criteria...
No Reduction in Recurrence Risk With Perioperative Aromatase Inhibitor Therapy in Postmenopausal Patients With HR-Positive Breast Cancer
As reported in The Lancet Oncology by Ian E. Smith, MD, and colleagues, the phase III POETIC trial found that perioperative aromatase inhibitor therapy did not reduce the risk of disease recurrence in postmenopausal women with hormone receptor (HR)-positive early breast cancer vs no perioperative...
Effect of Fertility Preservation on Reproductive Outcomes in Patients After Breast Cancer
In a Swedish nationwide cohort study reported in JAMA Oncology, Marklund et al found that women who had undergone fertility preservation had a higher live birth rate, were more likely to use assisted reproductive technology, and had better overall survival after breast cancer than women who had not ...
Case Series Study Explores Experiences of Transgender Patients With Cancer
In a retrospective case series reported in JAMA Oncology, Burns et al described clinical characteristics, treatment, experiences, and outcomes among transgender patients with cancer. As stated by the investigators, “Approximately 0.5% to 0.6% of the U.S. population identify as transgender, defined...
Machine Learning Algorithms May Help Predict Response to Immunotherapy in Patients With Advanced Melanoma
A study investigating a computational method that integrates deep learning on histology specimens with clinicodemographic variables has found that the artificial intelligence may help predict response to immune checkpoint blockade among patients with advanced melanoma. This computational approach...
FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
On November 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients aged 1 year and older and adult patients with relapsed or refractory high-risk...
Job Loss During Cancer: How to Cope and Continue Treatment
Job loss is stressful no matter the circumstances. Recently, millions of people have lost their jobs during the COVID-19 pandemic. To make matters more difficult, job loss in the United States can often mean a loss of health insurance. For people with cancer, losing a job is especially challenging...
ELNEC Project Reaches Historic Milestone in End-of-Life Care
The End-of-Life Nursing Education Consortium (ELNEC) project is ending 2020 by surpassing a goal established 20 years ago, reporting more than 1 million nurses and other professionals trained using the ELNEC curriculum. Administered through a partnership between the American Association of Colleges ...
Mohs Surgery vs Wide Local Excision for Trunk and Extremity Melanomas: Comparable Overall Survival Rates
A cohort study of 188,862 cases of all-stage melanomas of the trunk and extremities found no differences in overall survival between patients treated with Mohs micrographic surgery or with wide local excision.1 “These findings add to the existing body of evidence demonstrating that wide local...
Yes, Men Get Breast Cancer, Too
You could call it a sixth sense, but the moment I felt a lump in my left breast I knew it was cancer, although it would take several weeks to confirm the diagnosis. When I saw my primary cancer physician and told him of my concern, he said: “Don’t worry. Men don’t get breast cancer; it’s a woman’s...
No Benefit of Adjuvant Sorafenib in Intermediate- or High-Risk Renal Cell Carcinoma
In a phase III trial (SORCE) reported in the Journal of Clinical Oncology, Tim Eisen, FMedSci, FRCP, PhD, of Cambridge University Hospitals NHS Foundation Trust, and colleagues found no disease-free survival benefit with 3 years of sorafenib vs placebo as adjuvant therapy in patients with renal...
Medicaid Expansion May Be Linked to Lower Mortality Rates for Three Major Types of Cancer
In states that have expanded Medicaid availability as part of the Affordable Care Act (ACA), mortality rates for three major types of cancer are significantly lower than in states that have not expanded Medicaid availability, according to a recent study by researchers at Dana-Farber Cancer...
A Daughter of Immigrants Chooses a Challenging but Rewarding Career in Surgical Oncology
Nationally recognized oncologic surgeon Sandra L. Wong, MD, MS, FASCO, FACS, was born and raised in Stockton, California, a city on the San Joaquin River, in California’s Central Valley. “My parents were both immigrants, but unlike the stereotypical picture of hard-driving immigrant parents who...
Study Shows Equivalence of Sentinel Node Biopsy vs Neck Node Dissection in Operable Oral or Oropharyngeal Cancer
In the French phase III Senti-MERORL trial reported in the Journal of Clinical Oncology, Renaud Garrel, MD, PhD, of the University Hospital Center of Montpellier, France, and colleagues, found that sentinel node biopsy was equivalent to neck lymph node dissection in 2-year neck node...
What Is ‘Quality Oncology Care’ During the COVID-19 Pandemic?
My patient with metastatic colon cancer was sitting across from me after being absent for several months. His cancer had been under excellent control on chemotherapy, but now he was having worse pain and shortness of breath. Despite our calls, he had not kept his appointments. We were 6 feet apart, ...
